Drug repositioning as a viable business strategy. Biovista’s President A. Persidis interview to GEN’s editor in chief, John Sterling. “Prompted by the need to refurbish their pipelines at lower costs and to drive and sustain future profits, drug companies have turned to drug repositioning, or repurposing, as a means of drug rediscovery. The process of … Read More